PROGYNY INC (PGNY)
Health Care · women's health and fertility benefits management · NASDAQ
Progyny is a benefits platform that delivers superior fertility and women's health outcomes for employers through proprietary Smart Cycle treatment bundles, a selective specialist network, and integrated pharmacy services.
What PROGYNY INC does
Progyny is a global women's health and family building benefits platform that provides fertility, pregnancy, postpartum, menopause, and related health solutions to employers. The company operates through a differentiated Smart Cycle benefits plan design paired with a selective network of high-quality fertility specialists, member care advocacy, and an integrated pharmacy benefits solution (Progyny Rx). With over 590 employer clients covering approximately 7.2 million employees and dependents, Progyny delivers superior clinical outcomes and member satisfaction through data-driven active network management and comprehensive member support.
Themes: women's health and fertility benefits, family building / family formation, IVF and assisted reproductive technology, employee benefits and wellness, clinical outcomes optimization, pharmacy benefits management / reproductive health PBM, benefit plan design / benefits administration, employer benefits platform
Fundamentals
- Price$25.65 as of 2026-08-21 close
- Market cap$2.0B as of 2026-08-21
- 1-year return+10.9% 2025-08-21 close $23.13 → 2026-08-21 close $25.65
- P/E25.37 as of 2026-08-24
- Net margin+6.0% as of 2026-08-24
- Gross margin+24.6% as of 2026-08-24
- ROE+16.0% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+5.5% as of 2026-08-24
- Revenue CAGR (3y)+17.9% SEC XBRL
- Beta1.03 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How PGNY compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How PROGYNY INC looks technically
PROGYNY INC (PGNY) is trading 7.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 42 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 49, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 34, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 5 trading days ago. It is 22.4% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 7.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +7.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $29.05 | $29.05 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $23.86 | $23.86 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 25.095. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 42 trading days ago — a "golden cross", a bullish long-term signal | 42 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 49, with sellers in control | 48.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 34, neither overbought (above 70) nor oversold (below 30) | 33.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($25.09 to $31.82) — its "stochastic" reading is 8 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 8.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 25 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $33.06 | $33.06 |
|---|---|---|
| From the 52-week high | it is 22.4% below its 52-week high (its highest price of the past year) | -22.4% |
| Above the 52-week low | it is 59.3% above its 52-week low (its lowest price of the past year) | +59.3% |
| Below the 52-week high | it is 22.4% below its highest point of the past year | 22.4% |
| Since a 20-day breakout | it made a new 20-day low about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day high about 29 trading days ago | 29 sessions |
| All-time high | its highest closing price on record is $68.32 (set on 2021-11-05) | $68.32 |
| Given back of the 52-week move | over the past year its closes ranged ($16.30 to $32.36), and it has given back roughly a third of its rise from last year’s low — 42% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $21.92 to $22.43. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 41.8% |
| From the all-time high | it is 62.5% below its all-time high | -62.5% |
| Nearest price level | it is trading 1.7% above a support level at $25.20 — a price it turned at three times since 2024-09-17, most recently on 2026-08-07. Since 2024-08-21 it has 15 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.7% |
| All-time low | its lowest closing price on record is $13.29 (set on 2019-10-25) | $13.29 |
| Above the all-time low | it is 93.0% above its all-time low | +93.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 87% of the past ~6 months) | 87th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.11 between its high and its low — about 4.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.11 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $23.27 and $33.65 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $23.27 – $28.46 – $33.65 |
| Typical daily range (% of price) | its price moves about 4.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.3% |
| Stretch from the 200-day average | it is trading 1.6 daily ranges above its 200-day average price (7.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.96× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.3% since the prior reading | +1.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.04 toward buy |
Candlestick patterns
1
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.5% |
|---|---|---|
| Open gap | it gapped 15.4% below the previous close 10 sessions ago and has not traded back through the level it left behind at 30.21 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -15.4% |
| Gap filled | a 2.4% gap up opened on 2026-08-20 has been "filled" today — price traded back through the level the gap left behind, and it took 1 session to close | today |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 22.8 percentage points (the stock lost 20.4% while the market gained 2.3%) | -22.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 0.8 percentage points (the stock gained 3.9% while the market gained 3.1%) | +0.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 11.2 percentage points (the stock gained 22.3% while the market gained 11.1%) | +11.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 9.6 percentage points (the stock gained 10.9% while the market gained 20.5%) | -9.6% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, MACD momentum is negative — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 18.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 10% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $23.39 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +9.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% below the average price paid since it last reported on 2026-08-06 (its 8-K), so the typical buyer over that stretch is under water. That average is $26.96 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -4.9% |
Price levels it has turned at before
PGNY last closed at $25.65 on 2026-08-21. Since 2024-08-21 it has turned at 15 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $25.20 | Support | 1.7% below the last close | turned there three times · 2024-09-17 to 2026-08-07 |
| $26.52 | Resistance | 3.4% above the last close | turned there three times · 2025-02-28 to 2026-06-01 |
| $24.28 | Support | 5.3% below the last close | turned there three times · 2024-09-03 to 2026-05-11 |
| $23.86 | Support | 7.0% below the last close | turned there five times · 2025-02-04 to 2026-01-16 |
| $27.47 | Resistance | 7.1% above the last close | turned there four times · 2025-11-17 to 2026-06-16 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $25.09.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $42.06 and $52.54 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $25.09.
This reading has stood for 6 trading days, since 2026-08-14.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · Analyst price target recently RAISED · beating the market · At the bottom of its 14-day range (stochastic below 20) · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.42 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$34.25 range $30.00 – $40.00; median $35.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PGNY
- Consensus EPS estimate$0.5089 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Failure to meet publicly announced guidance could cause stock price decline; actual results depend on difficult-to-predict factors including macroeconomic conditions, medication shortages, and utilization trends","Highly competitive market with larger, more established competitors that have greater financial and marketing resources; risk of emerging fertility-focused PBMs and competitors developing similarly robust data-driven platforms","Reliance on retention of existing clients and continued member satisfaction; loss of major clients or decline in member satisfaction could adversely impact business performance"]
What changed in the latest 10-Q
AI-assisted comparison of PGNY's 10-Q filed 2026-05-08 against the prior one filed 2025-11-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-08) describes Progyny as 'a global leader in women's health and family building solutions' vs. older filing's 'a leading benefits management company specializing in fertility, family building and women's health benefits solutions in the United States'
- Newer filing adds language about 'specialists' (without 'and') in the Overview section describing pursuit of 'most effective treatment across life's milestones from the best providers and specialists'
- Newer filing updates client count to 'more than 590' vs. older filing's 'over 550'
- Newer filing updates covered lives to 'approximately 7.2 million' vs. older filing's 'approximately 6.7 million'
- Newer filing updates fertility benefits NPS to '+81' vs. older filing's '+79'
- Newer filing updates Progyny Rx NPS to '+79' vs. older filing's '+84'
- Newer filing references 'our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 27, 2026' vs. older filing's 'fiscal year ended December 31, 2024, filed with the SEC on March 3, 2025'
- Newer filing adds detailed list of specific industries served in 'Our Clients' section, listing 'technology, consumer retail, e-commerce, industrial, healthcare, media, insurance, legal, food and beverage, financial services, life sciences, professional services, government services, union, energy, manufacturing, logistics, transportation, aerospace, real estate, nonprofit and hospitality sectors'
- Removed:
- Older filing's description of clients ranging 'from approximately 1,000 to 600,000 employees' is revised to 'from approximately 1,000 to 300,000 employees' in newer filing
- Older filing's final paragraph about population-based component mentioning PEPM fee details is truncated/removed in newer filing excerpt provided
- Reworded:
- Newer filing: 'preimplantation genetic testing, in the case of in vitro fertilization, or IVF' vs. older filing: 'in the case of in vitro fertilization, or IVF, preimplantation genetic testing' (parenthetical word order change)
- Newer filing moves description of Progyny's nature ('global leader') to first sentence of Overview, whereas older filing places mission statement first
- IVF multiples rate changed from '5.5% / 4.9% / 2.1%' in older filing to '5.8% / 5.4% / 2.1%' in newer filing in the outcome table
- Notes:
- The older filing text appears truncated at the end of the 'Our Clients' section, cutting off mid-sentence in the population-based component discussion
- Comparison is based on available text; full document scope may differ
Risk Factors
- Reworded:
- Guidance date changed from 'November 6, 2025' (filed 2025-11-07) to 'May 7, 2026' (filed 2026-05-08)
- Guidance period changed from 'fourth quarter of 2025 and full year 2025' (filed 2025-11-07) to 'second quarter of 2026 and full year 2026' (filed 2026-05-08)
- Page number changed from '41' (filed 2025-11-07) to '40' (filed 2026-05-08)
- Notes:
- Both texts are truncated at the end with identical incomplete sentences ('If a partner experiences sizable growth following consolidation, it may determine that it no'), making full comparison of later content impossible
- The substantive risk factor language remains identical between the two filings; only the guidance date, period, and page number differ
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 10 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 10 sells ($621339) — 6 selling insiders
- Last 180 days0 buys · 12 sells ($1M) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-14. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PGNY's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 1 matched disclosure for PGNY from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding PGNY as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 22,423,246
- Reported value $380,746,708
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 1 increased, 4 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
PGNY had 4,485,539 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
PGNY had 5.85% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.61 days to cover at the same settlement.
- Reported short interest (shares) 4,485,539
- Short interest (% of shares outstanding) 5.85%
- Prior settlement (shares) 4,629,299
- Reported change -3.11%
- Days to cover (reported) 4.61
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- UnitedHealth Group (UNH)
- Cigna (CI)
- Aetna
- Fertility-focused benefits vendors in the market
- Maternity and reproductive health service providers
- Venture capital or private equity-backed fertility benefits companies
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PGNY vs…
Frequently asked questions
What does PROGYNY INC (PGNY) do?
Progyny is a global women's health and family building benefits platform that provides fertility, pregnancy, postpartum, menopause, and related health solutions to employers. The company operates through a differentiated Smart Cycle benefits plan design paired with a selective network of high-quality fertility specialists, member care advocacy, and an integrated pharmacy benefits solution (Progyny Rx).
What sector is PROGYNY INC (PGNY) in?
PROGYNY INC (PGNY) is classified in the Health Care sector. Its industry is women's health and fertility benefits management. It trades on NASDAQ.
Who are PROGYNY INC's (PGNY) competitors?
Notable peers of PROGYNY INC (PGNY) include UnitedHealth Group, Cigna, Aetna, Fertility-focused benefits vendors in the market and Maternity and reproductive health service providers. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in PGNY?
Yes — we hold 1 matched STOCK Act disclosure for PGNY from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is PROGYNY INC (PGNY) overbought or oversold right now?
PROGYNY INC (PGNY) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 34, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PGNY come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.